Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)-MedSci.cn

Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)

Colomba, E; Silva, CAC; Le Teuff, G; Benchimol-Zouari, A; Guida, A; Derosa, L; Raynard, B; Escudier, B; Albiges, L

ANNALS OF ONCOLOGY, 2019; 30 ():

科室
- - 订阅+
  - 更多科室
工具
服务